Effectiveness and safety of orforglipron, an oral drug activating GLP-1 receptors, on heart and metabolism health: a combined analysis of studies

The twenty-first century is experiencing a pandemic of intertwined cardiometabolic disorders, principally Type 2 Diabetes Mellitus (T2D) and obesity [1, 2], driving atherosclerotic cardiovascular disease (ASCVD), the leading cause of global mortality [3, 4]. Shared pathophysiology, including insulin resistance, chronic inflammation, and endothelial dysfunction, requires therapies targeting comprehensive risk reduction [5, 6]. Incretin-based therapies that leverage gut-derived glucagon-like peptide-1 (GLP-1) have transformed this paradigm [6, 7].GLP-1 Receptor Agonists (GLP-1 RAs), injectable peptide analogues resistant to Dipeptidyl Peptidase-4 (DPP-4) degradation [8] have demonstrated cardiovascular protection in recent cardiovascular outcome trials: LEADER (liraglutide) [9], SUSTAIN-6 (Semaglutide) [10], and REWIND (Dulaglutide) [11], reducing MACE by 12–15% via risk factor improvement and pleiotropic vascular effects [12]. Despite injectable GLP-1 receptor agonists’ proven efficacy and cardioprotection, needle anxiety limits adherence. Oral agents like orforglipron overcome this barrier, potentially improving persistence by 20–30% and broadening ASCVD prevention [13, 14]. Oral semaglutide, co-formulated with Sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC), achieved marked bioavailability but requires fasting and 30-minute post-dose restrictions, reducing flexibility [13, 15]. Small-molecule, non-peptide GLP-1 RAs eliminate peptide limitations, enabling oral administration, improving stability, reducing manufacturing costs, and potentially enhancing patient adherence [16–18]. Orforglipron (LY3502970), a potent full agonist with G protein-biased signaling, supports once-daily oral dosing. Preclinical studies showed cAMP stimulation, glucose-lowering, and appetite suppression comparable to exenatide [19, 20], Phase 1a confirmed tolerability and pharmacodynamics in healthy subjects, including weight loss and reduced glucose excursion [21]. Building on this, the Phase 1b, multiple-ascending-dose study in patients with T2D further confirmed dose-dependent improvements in glycemic control and body weight reduction over 12 weeks, providing the first critical evidence in the target population [22]. Phase 2 in T2D achieved up to 1.6% HbA1c and 10.1% weight reduction at 26 weeks [23]. ACHIEVE-1 (Phase 3) in early T2D confirmed significant HbA1c reduction and weight loss at 40 weeks, solidifying its role as a reliable treatment option for glycemic control and weight management [24].

After efficacy was proven in patients with T2D, the utility of Orforglipron in dedicated weight management of patients without T2D was rapidly explored. In non-diabetic obesity, Phase 2 yielded > 10% weight loss at 26 weeks [25]. This magnitude of weight loss compares favorably with established injectable GLP-1 RAs and dual agonists [26]. Furthermore, the confirmatory Phase 3 ATTAIN-1 trial in the non-diabetic obesity population demonstrated sustained, clinically transformative weight reduction over 72 weeks. This trial reinforced the high efficacy and consistent dose-responsive relationship of Orforglipron as a standalone weight management therapy [27]. Importantly, across both the T2D and obesity development programs, exploratory analyses confirmed that Orforglipron is associated with favorable changes in multiple secondary cardiovascular risk biomarkers, including improvements in blood pressure, lipid profiles, and systemic inflammatory markers, suggesting the potential for broad cardiometabolic benefit beyond weight or glucose reduction [28].

Although individual Phase 2/3 trials and previous meta-analyses have established the efficacy of Orforglipron on glycemic control and weight loss in patients with type 2 diabetes and/or obesity, the evidence base remains fragmented across multiple reports, diverse dosing regimens (ranging from 3 mg to 45 mg), and varied treatment durations. A synthesized, quantitative appraisal of the totality of the clinical trial evidence is essential for two reasons. To powerfully estimate unified treatment effects on HbA1c, cholesterol, blood pressure, and weight loss independent of dose, while extending the insights gained from Orfoglipron by systematically evaluating its impact on blood pressure reduction and ASCVD risk stratification ultimately offering clinicians, quantitative evidence to guide cardio metabolic and cardiovascular risk management [29].

This meta-analysis consists of four trials in obesity or T2D patients shows that oral Orforglipron, a non-peptide GLP-1RA, delivers consistent, clinically meaningful weight loss and glycemic improvements [23–25, 27].

This systematic review and meta-analysis provides the first quantitative synthesis of the cardiometabolic efficacy and safety of orforglipron, the novel oral non-peptide GLP-1 receptor agonist currently in development. In analysis of pooled data from four large phase 2 and phase 3 placebo-controlled trials involving more than 4,500 participants with type 2 diabetes (T2D) or obesity [23–25, 27], orforglipron produced clinically significant, dose-dependent improvements across virtually all modifiable atherosclerotic cardiovascular disease (ASCVD) risk factors: body weight − 6.08% (95% CI -7.68 to -4.47, reaching − 8.12% to − 9.31% at 24–45 mg doses), HbA1c -0.85% overall (95% CI -1.53 to -0.18; up to -1.36% at higher doses), systolic blood pressure − 4.32 mmHg (95% CI -5.61 to -3.03), LDL-cholesterol − 4.14% (95% CI -6.38 to -1.91), triglycerides − 10.90% (95% CI -14.36 to -7.43), VLDL-cholesterol − 10.81% (95% CI -14.10 to -7.51), and a + 3.31% rise in HDL-cholesterol (95% CI + 1.66 to + 4.97). The very low or absent heterogeneity (I² = 0%) observed for systolic blood pressure, LDL-cholesterol, triglycerides, and VLDL-cholesterol is noteworthy and can suggest a highly predictable class effect driven by orforglipron’s unique non-peptide structure and G-protein-biased signaling [16, 17]. However, with only four trials, confidence intervals around I² are wide, precluding definitive claims of perfect between-study consistency. Heterogeneity in lipid and blood-pressure outcomes (I² up to 74%) was driven by expected population differences: the two T2D trials had higher baseline LDL-C and total cholesterol at baseline and longer duration (72 weeks) than the two non-diabetic obesity trials (52 weeks), accounting for the larger atherogenic-lipid reductions and smaller HDL increases in the T2D cohort (Table S1).

These effect sizes are clinically meaningful when placed in context. A ≥ 5% body weight reduction, as achieved across all doses ≥ 12 mg, is associated with substantial improvements in comorbidities such as hypertension, dyslipidemia, and sleep apnea [35]. Notably, meta-analyses have shown that a 1 mmol/L reduction in LDL-cholesterol corresponds to a highly significant 22% risk reduction in major cardiovascular events [36]. Similarly, the HbA1c reduction exceeds the 0.5% threshold linked to microvascular risk reduction in T2D guidelines [5]. The pooled systolic blood pressure reduction (-4.32 mmHg; 95% CI -5.61 to -3.03, up to -5.78 mmHg at higher doses) approximates the 5 mmHg threshold associated with an approximately 10% relative risk reduction in major cardiovascular events [37]. More critically, applying the pooled changes observed in this analysis to the 2013 ACC/AHA Pooled Cohort Equations (or SCORE2-Diabetes in European cohorts), Orforglipron reduces the estimated 10-year ASCVD risk by 15.3–20.5% relative to placebo (Table S3) [38–40]. This magnitude aligns closely with the 12–26% relative risk reductions in major adverse cardiovascular events (MACE) observed in landmark cardiovascular outcome trials of injectable GLP-1 receptor agonists (LEADER, SUSTAIN-6, REWIND, SELECT) [9–11, 41]. However, definitive evidence of cardiovascular protection requires dedicated outcome trials, which have not yet been initiated for Orforglipron. Mediation analyses from these trials attribute 50–70% of the MACE benefit to similar surrogate improvements in weight, HbA1c, blood pressure, and lipids, with the remainder potentially due to pleiotropic effects such as reduced inflammation (e.g., hsCRP reductions of 26–42% observed in orforglipron’s exploratory analyses) [12, 27]. GLP-1 receptor agonists significantly reduce MACE and all-cause mortality. Liraglutide and dulaglutide show the broadest CV benefit (MACE, CV death, MI, stroke, and heart failure), followed by subcutaneous semaglutide and albiglutide; oral semaglutide and exenatide show favorable trends.

Orforglipron, a novel once-daily oral small-molecule GLP-1RA, has not yet reported MACE outcomes from its ongoing CVOT. It remains highly promising for future CV protection due to its non-peptide structure, high bioavailability, food-independent dosing, and superior weight-loss efficacy comparable to injectable agents [42].

Direct comparison with established GLP-1 receptor highlights Orforglipron’s emerging competitive position (Table S17). At higher doses, orforglipron’s weight loss (− 8.25% to − 9.31%) approaches weekly subcutaneous semaglutide 2.4 mg (-12.4%)[37] and clearly exceeds oral semaglutide 14 mg (-3.4%) [10, 43]. In addition, its systolic blood pressure reduction (− 3.2 to − 5.8 mmHg) and lipid effects (LDL-C -10.4% to -8.45%, triglycerides − 13.60% to 14.45%) equal or surpass those of injectable semaglutide and are substantially larger than those reported for oral semaglutide [10, 43, 44]. Despite lower absolute weight loss, Orforglipron’s lipid and blood-pressure benefits approach the magnitude seen with the dual GIP/GLP-1 receptor agonist tirzepatide [45, 46], suggesting that its non-peptide, G-protein-biased signaling profile may confer disproportionate cardiometabolic effects beyond those explained by weight reduction alone [16–18]. Notably, whereas weight loss and HbA1c reduction remain dose-dependent up to 45 mg, beneficial effects on systolic blood pressure, LDL-cholesterol, triglycerides, and VLDL-cholesterol plateau at 12–24 mg with zero heterogeneity. This suggests that maximal ASCVD risk reduction may be achieved at lower doses than those needed for maximal weight loss, likely due to orforglipron’s G-protein-biased signaling that preferentially enhances hepatic and vascular effects relatively independent of central appetite suppression, This mechanism supported by preclinical data indicate enhanced hepatic GLP-1 receptor activation, potentially driving direct triglyceride-lowering via reduced VLDL secretion, independent of caloric intake [19, 20]. This mechanistic distinction likely explains the low heterogeneity in lipid and blood pressure outcomes (I² = 0% for SBP, LDL-C, VLDL-C, and triglycerides), in contrast to the high, dose-driven heterogeneity observed for body weight (I² = 84%) and HbA1c (I² = 96%). Consequently, near-maximal cardiometabolic protection appears achievable at modest doses (12–24 mg), whereas higher doses (≥ 36 mg) are required primarily for optimal glycemic control and weight loss. This profile supports a personalized dosing strategy: lower doses may suffice for cardiovascular risk reduction, while higher doses can be reserved for patients prioritizing intensive weight management or diabetes control. An intriguing pattern emerged in lipid responses across populations. In patients with type 2 diabetes (Frias 2023; Rosenstock 2025), orforglipron produced markedly greater reductions in LDL-cholesterol (-9.4% to -13.3%) and total cholesterol (-9.4% to -10.8% %) than in non-diabetic obesity (-3.5% to -6.7% and − 2.1 to -5.4%, respectively). Conversely, HDL-cholesterol increased more in the non-diabetic obesity trials (+ 2.8 to + 4.1%) than in T2D (-0.8 to + 3.2%), while triglyceride reductions were similar in both groups (-8.3 to -13.9%). This differential profile suggests that orforglipron particularly improves the most adverse lipid fractions in patients with type 2 diabetes, while favoring an HDL-raising effect in non-diabetic obesity, reinforcing its versatile cardiometabolic benefit across the entire spectrum.

Gastrointestinal adverse events remain the principal tolerability limitation, aligning with the GLP-1 receptor agonist class, albeit toward the higher end of the spectrum (nausea RR 5.22 [95% CI 2.60–10.48], vomiting RR 3.24 [95% CI 2.69–3.90], eructation RR 6.80 [95% CI 3.76–12.29]) [44, 47]. A 2024 network meta-analysis ranks orforglipron highest for nausea risk among oral GLP-1 RAs in non-diabetic patients, potentially due to its rapid absorption profile [44]. Overall discontinuation due to any adverse event was 7.8% with orforglipron versus 2.7% with placebo (RR 2.99, 95% CI 2.07–4.33). Importantly, rates were markedly lower in the two phase 3 trials (4.4% − 7.8%) than in phase 2 studies (10% − 17%), reflecting the benefit of slower dose-escalation schedules now implemented in later-stage development [23–25, 27]. Orforglipron’s non-peptide structure eliminates the need for SNAC and fasting restrictions, delivering absolute oral bioavailability of 20–40% compared with only 0.4–1% for oral semaglutide. This yields markedly more consistent systemic exposure resulting in pharmacokinetic stability that contributes to the near-absent heterogeneity observed in systolic blood pressure and lipid effects (I² = 0% for SBP, LDL-C, triglycerides, and VLDL-C), a clear advantage over current oral peptide formulations [10, 13, 15, 22]. This practical advantage may translate to improved long-term adherence, an outcome repeatedly identified as the major barrier to sustained benefit with current injectable therapies in real-world registries [47].

Beyond efficacy and safety, orforglipron’s profile holds particular promise for broadening access in underserved populations. In the global obesity-T2D pandemic, where ASCVD disproportionately affects ethnic minorities and low-income groups with limited healthcare access [1–4], an affordable oral agent without refrigeration or injection needs could bridge equity gaps. Exploratory data from phase 3 trials show consistent benefits across subgroups (e.g., BMI ≥ 35 kg/m², HbA1c > 8%) [27, 28] and its non-peptide stability may lower manufacturing costs, facilitating scalability in resource-constrained settings [17, 18]. If approved (with FDA submissions anticipated in late 2025), orforglipron could complement lifestyle interventions in primary prevention, especially where there are barriers to subcutaneous injections.

The strengths of this meta-analysis include the incorporation of the most recent phase 3 data (ACHIEVE-1 and ATTAIN-1) [24, 27], detailed dose–response analyses that resolve sources of heterogeneity (e.g., via leave-one-out sensitivity), and the exceptionally consistent effects on blood pressure and lipids (I²=0% for all lipid fractions and SBP), supported by high GRADE certainty ratings. (Table S2). We acknowledge several limitations. Only four trials were available, with the longest extending to 72 weeks, limiting our ability to assess long-term durability or detect rare adverse events. Moreover, hard cardiovascular, renal, and heart-failure outcomes have not yet been reported, and a dedicated CVOT—analogous to SURPASS for tirzepatide—has not been initiated. Surrogate risk equations, while validated, cannot substitute for observed event reduction [39, 40], and the moderate GRADE certainty for weight/HbA1c (due to inconsistency) warrants caution. Finally, with only four studies, funnel plots for publication bias were infeasible.

In conclusion, orforglipron represents a potential paradigm shift in cardiometabolic pharmacotherapy: a once-daily oral small-molecule that combines unparalleled ease of administration with comprehensive, highly consistent reductions in weight, glycemia, blood pressure, and the full spectrum of atherogenic lipids Its effects rival or exceed those of oral semaglutide and approach injectable benchmarks, positioning it as a versatile option for personalized therapy (e.g., 24 mg for weight, 45 mg for SBP). If dedicated cardiovascular outcome trials-expected post-approval will confirm translation of these surrogate improvements into MACE reduction similar to established injectable GLP-1 receptor agonists, orforglipron could dramatically expand access to high-efficacy GLP-1 based therapy, particularly among injection-averse patients and in resource-constrained settings. This novel treatment can favorably modify major drivers of ASCVD risk with a single daily pill positioning it as a transformative candidate for future guideline-directed medical therapy in the escalating global burden of obesity-related cardiovascular disease.

Below is the link to the electronic supplementary material.

Not applicable.

AA and AG: conceptualization, methodology, formal analysis, investigation, writing - original draft, visualization. GP and AF: investigation, data curation, validation, writing - review & editing. PS and IC: data curation, formal analysis, validation. AG: investigation, resources. RF: supervision, writing - review & editing. All authors read and approved the final manuscript.

No external funding.

The datasets generated and/or analyzed during the current study are not publicly available institution policy but are available from the corresponding author on reasonable request.